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Introduction {#sec001}
============

Within the last 10 years, treatment of infectious diseases such as wound infections of the skin and the mucous membranes has become increasingly more complicated and ineffective due to the emergence of drug-resistant bacteria. In the 2016 Review on Antimicrobial Resistance, an alarming scenario was built up presaging that by 2050 10 million people could die per year caused by multidrug-resistant bacteria \[[@pone.0223925.ref001]\]. Eradication of multi-resistant superbugs like the so-called "ESKAPE"-pathogens is one of the major clinical challenges of the twenty-first century \[[@pone.0223925.ref002]\]. One of the pathogens being often causative for nosocomial infections like catheter-associated urinary tract infections is the Gram-positive coccus *Enterococcus faecalis* \[[@pone.0223925.ref003]\]. *E*. *faecalis* combines many virulence factors like intrinsic resistances to several classes of antibiotics \[[@pone.0223925.ref004]\]. Furthermore, it is known for its ability to gain resistance in a relatively short amount of time \[[@pone.0223925.ref005]\]. In addition, *E*. *faecalis* is able to form biofilms on both, inanimate and living surfaces which raises tolerance and decreases susceptibility against environmental influences or antimicrobial measures \[[@pone.0223925.ref006], [@pone.0223925.ref007]\].

In general, bacterial biofilms are found on natural surfaces as well as on artificial ones like inside of catheters or on other implants \[[@pone.0223925.ref008]\]. Bacteria in such a sessile biofilm-mode are known to be much more tolerant towards antimicrobial approaches than their planktonic counterparts \[[@pone.0223925.ref009]\]. A primary mechanism for this enhanced tolerance is the extracellular polymeric substance (EPS) which bacteria are embedded in and which can act as a diffusion barrier for antimicrobial agents \[[@pone.0223925.ref010]\].

Therefore, novel treatment modalities that are capable of killing pathogens in biofilms with less or even no risk of inducing resistances are desperately needed \[[@pone.0223925.ref011]\]. Accordingly, already in 2011 a review published by Karen Bush *et al*. in *Nature Reviews Microbiology* had pointed out that „investigation of novel non-antibiotic approaches for the prevention of and protection against infectious diseases should be encouraged and that such approaches must be high-priority research" \[[@pone.0223925.ref012]\]. Therefore, new approaches must be developed that are capable of eliminating bacteria successfully, independently of their resistance patterns \[[@pone.0223925.ref013]\]. In this light, a novel therapeutic option may be cold atmospheric plasma (CAP), which is a highly innovative technology due to the point that no resistances have been induced in bacteria against CAP so far \[[@pone.0223925.ref014]\]. CAPs are partly ionized gases (with a typical ionization fraction of one ion or electron per a billion neutral atoms or molecules) producing a reactive mix by interacting with the surrounding air and being composed of electrons, ions, neutrons, excited atoms and molecules, reactive oxygen and nitrogen species, and UV light \[[@pone.0223925.ref015]\]. Depending on the respective plasma source technology, the carrier gas (here: ambient air), the plasma operating parameters and the set-up modalities (like transportation mode, volume etc.), the composition as well as the concentrations of the produced plasma species vary. This means, that CAPs can be "designed" to a certain extent and that different compositions of reactive species can be produced by changing input parameters such as carrier gas, voltage, frequency etc. \[[@pone.0223925.ref016]\].

CAPs are known to effectively inactivate bacteria and fungi (independent of their resistance profiles towards conventional antimicrobials as well as on different surfaces and in biofilms), spores and viruses \[[@pone.0223925.ref017], [@pone.0223925.ref018]\]. Furthermore, it could be shown that CAP doses can be found where pathogens can be inactivated without mammalian tissues being harmed or without changing the characteristics of the respective materials that bacteria are attached to \[[@pone.0223925.ref019], [@pone.0223925.ref020]\]. Due to these results and, moreover, as CAP operate at low temperatures (5--10°C above room temperature only), various applications in hygiene (*e*.*g*. sterilization of medical equipment, hand disinfection *etc*.) and in clinical practice (*e*.*g*. treatment of infected wounds) are currently under investigation in the plasma medicine community \[[@pone.0223925.ref021], [@pone.0223925.ref022]\].

Consequently, plasma medicine--an evolving research field investigating CAP and their potential application in hygiene and medicine--has attracted a lot of interest in the past few years. However, the actual mechanisms of the antimicrobial action of CAP are still mostly unknown \[[@pone.0223925.ref023]\]. Furthermore, the antimicrobial efficacy of CAP against microbial biofilms is still not sufficiently explored and only very few studies have been performed up to this point \[[@pone.0223925.ref024]--[@pone.0223925.ref028]\]. Recently, our group showed that DNA damage seems not to be the primary mechanism of bacterial cell death upon CAP treatment because *Deinococcus radiodurans*, which is known to have a very efficient DNA repair mechanism, can easily be killed by CAP \[[@pone.0223925.ref029]\], whereas this bacterium survives ionizing radiation up to 5000 Gy without being harmed \[[@pone.0223925.ref030]\]. Taking into consideration that the external structures like cell walls and cytoplasmic membranes most likely are destroyed before nucleic acids can be targeted, it seems reasonable that these outer cellular structures may be first-line targets of CAP \[[@pone.0223925.ref031]\].

Therefore, the aims of this study were (1) to investigate the antimicrobial efficacy of CAP with a novel surface micro-discharge (SMD) technology in a thin-film design towards *E*. *faecalis* in planktonic cultures as well as in biofilms and (2) to evaluate whether CAP treatment leads to cytoplasmic membrane damage as measured by leakage of cytoplasmic components upon treatment.

Material and methods {#sec002}
====================

Thin-film surface micro-discharge plasma source {#sec003}
-----------------------------------------------

In this study, a CAP plasma source prototype was used under ambient conditions (natural fluctuation room with ≈21°C). This prototype consists of one surface micro-discharge (SMD) plasma source with thin-film design composed of an insulator plate made out of Al~2~O~3~ (thickness 0.25 mm), a high voltage (= HV) electrode coated with Cu and Sn (thickness of 3.0 μm and 1.0 μm, respectively) electrode and a structured electrode, meaning an electrically grounded stainless-steel mesh electrode (basic material 1.4310, thickness 0.5 mm, square-shape structured). The novel thin-film design is the result of further development of the SMD plasma source described by Shimizu et al. \[[@pone.0223925.ref032]\]. The new design provides a technique that can be manufactured in series with minimized height. Therefore, the plasma source only needs a minimum of power that allows for battery-driven operation. The plasma is produced homogenously on the structured electrode by applying high sinusoidal AC voltage of 3.5 kV~PP~ at a frequency of 4.0 kHz between the HV electrode and the structured electrode. In contrast to DBD-technology (dielectric-barrier-discharge), there is no current through the treatment object. The power consumption of this plasma source is about 0.5 to 1 W (depending on the surrounding humidity) and contains mainly reactive oxygen species.

The plasma source (composed of HV electrode, insulator plate and structured electrode) itself is embedded in a plastic case to ensure safe and easy handling during the experimental procedures ([Fig 1](#pone.0223925.g001){ref-type="fig"}). The size of the plasma source including the outer rim is 39.5 mm x 39.5 mm. The size of the plasma production area on the structured electrode is 29.5 mm x 29.5 mm. A spacer (inner height 10 mm, inner diameter 40 mm, outer diameter 50 mm, treatment area 12.56 cm^2^, material Polytetrafluorethylene) which is attached to the plasma source and surrounds the structured electrode, allows the formation of a (semi-) closed volume of 126 mL (between plasma source and biological sample) so that the produced plasma species are confined inside.

![Schematic view of the plasma source prototype with surface micro-discharge-technology (SMD) in thin-film design.\
Ambient air is used and an area of interest of 12.56 cm^2^ can be treated.](pone.0223925.g001){#pone.0223925.g001}

The plasma source is placed above the sample. The transportation of the generated plasma species to the sample is carried out by diffusion and thermal convection. Depending on the experiments, treatment periods ranged between 1 min and 10 min in this study.

Bacterial culture {#sec004}
-----------------

*Enterococcus faecalis* (DSM 2570, ATCC 29212) was obtained from the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) to be used for these experiments. *E*. *faecalis* was maintained on Müller-Hinton agar plates. For inoculation, one single colony was picked, suspended in 5 ml Brain Heart Infusion broth (BHI; Sigma-Aldrich, St. Louis, MO, USA) and incubated over-night at 37°C on an orbital shaker (180 rpm). Afterwards, cultures were harvested by centrifugation (10 min, 3000 rpm; Table centrifuge Universal 320R, Hettich Germany), resuspended in phosphate-buffered saline (PBS; Dulbecco's Phosphate Buffered Saline, Sigma-Aldrich, St. Louis, MO, USA) and the optical density (OD) was measured at 600 nm by means of a spectrophotometer (SPECORD 50 Plus, Analytik Jena, Jena, Germany). Bacterial suspensions were adjusted to an OD of 0.6 for planktonic experiments or to an OD of 0.13 for biofilm formation, respectively.

CAP treatment towards planktonic bacteria on agar plates {#sec005}
--------------------------------------------------------

*E*. *faecalis* suspensions were used at an OD of 0.6. 100 μL of bacterial suspension were spread on Müller-Hinton agar plates and then exposed to CAP treatment (for 1, 3, 5 or 10 min), while the spacer mentioned above ensured a distance of 10 mm between plasma source and samples. After subsequent incubation of the agar plates at 37°C for 24 h, colony forming units (CFUs) were evaluated. The area of interest was calculated based on the inner diameter of the spacer (40 mm) related to the whole area of the agar plates. For computation of log~10~-reduction rates, CFUs of serial dilutions of the original bacterial suspensions at OD = 0.6 were evaluated.

Biofilm formation {#sec006}
-----------------

*E*. *faecalis* biofilms were formed as it has been described earlier in detail \[[@pone.0223925.ref033], [@pone.0223925.ref034]\]. Briefly, over-night cultures of *E*. *faecalis* (OD = 0.13) were harvested by centrifugation and resuspended in the complete saliva (CS) broth originally described by Pratten *et al*. \[[@pone.0223925.ref035]\], which was modified by adding 0.1% (w/v) sucrose \[[@pone.0223925.ref033], [@pone.0223925.ref034]\]. 2 mL of this bacterial suspension in CS broth were mixed with 1 mL fetal calf serum (FCS; Pan-Biotech GmbH, Aidenbach, Germany) and added to sterile polystyrene petri dishes (35 mm x 10 mm; Primaria^TM^ Easy Grip Cell Culture Dish, Corning, NY, USA). Biofilms were incubated at 37°C under aerobic conditions without shaking for 24, 48 or 72 h, respectively. For biofilms cultured for more than 24 h, growth medium was changed every 24 h.

After the respective culture period, growth medium was carefully discarded with a pipette. Afterwards, the biofilms were treated with CAP for 1, 3, 5 or 10 min, respectively. For biofilm inactivation a spacer adjusted to a height of 20 mm was placed over the polystyrene petri dish and the CAP plasma source was placed on top of it. The biofilm was removed by scratching the biofilm from the bottom of the plastic well as well as by pipetting up and down repeatedly. Removal of all attached cells was checked by using light microscopic observation of the bottom of each petri dish. For separation of aggregated bacteria, the tubes were vortexed for 10 s and placed in an ultrasonic (35 kHz) water bath chamber (USR 30 H, Merck Eurolab GmbH, Grafing, Germany) for 10 min. Subsequently, serial tenfold dilutions were prepared (up to 10^−16^) and aliquots (3x 20 μL) were plated on Müller-Hinton agar plates according to the method described by Miles *et al*. \[[@pone.0223925.ref036]\]. CFU were evaluated after aerobic incubation for 24 h at 37°C.

UVC radiation and treatment with chlorhexidine digluconate (CHX; Sigma-Aldrich, St. Louis, MO, USA) were used as positive controls. UVC radiation was performed with a DNA crosslinker operating at 254 nm (Biometra GmbH, Göttingen, Germany; radiation doses: 0.005 J/cm^2^, 0.195 J/cm^2^ or 0.26 J/cm^2^). CHX was used at concentrations of 0.2% or 2% and incubation was carried out for 5 min.

Spectroscopic measurements for release of nucleic acids upon CAP treatment {#sec007}
--------------------------------------------------------------------------

To evaluate whether CAP treatment leads to damage of cytoplasmic membranes, release of nucleic acids from the cytoplasm was measured spectroscopically at 260 nm as described earlier \[[@pone.0223925.ref037], [@pone.0223925.ref038]\]. Biofilms were cultured as described above and treated with CAP for 5 or 10 min, respectively. As a positive control, the biofilms were scraped, resuspended in PBS and incubated with 100 μL lysozyme (40,000 units/mg; Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37°C. Then, 100 μL Proteinase K (7.0--14.0 units/mg; Sigma-Aldrich, St. Louis, MO, USA) and 200 μL 1% sodium dodecyl sulfate (Carl Roth GmbH + Co. KG, Karlsruhe, Germany) were added and incubated for another 30 min at 37°C. The biofilms were brought to suspension in 1 mL PBS and transferred to 1.5 mL Eppendorf tubes. After sonication in an ultrasonic water bath chamber (Sonorex Super RK 102 H; 35kHz) for 10 min, the tubes were centrifuged (13.000 rpm; 5 min) and the supernatants were collected and evaluated for nucleic acid release by assessing the OD at 260 nm with a NanoDrop^TM^ 2000 spectrophotometer (PEQLAB, Erlangen, Germany).

Data analysis {#sec008}
-------------

CFU results are shown as medians, 1^st^ and 3^rd^ quartiles and were calculated using SPSS for Windows, v. 25 (SPSS Inc., Chicago, IL, USA) from the values of at least six independent experiments. In the figures, horizontal solid and dashed lines show 3 and 5 log~10~ steps reduction of CFU compared to the untreated control (7.3 x 10^10^ CFU in median). Medians on or below these lines mean a bacterial reduction by 3 log~10~ (≥99.9%) or by 5 log~10~ (≥99.999%) or higher, respectively. According to the guidelines of infection control this means a biologically relevant antimicrobial activity or a disinfectant effect, respectively \[[@pone.0223925.ref039]\]. Results from spectroscopic measurements are depicted as medians, minima and maxima, and were calculated by SPSS from the values of three independent experiments at least.

Results {#sec009}
=======

Antimicrobial assay towards planktonic *E*. *faecalis* on agar plates {#sec010}
---------------------------------------------------------------------

Firstly, we investigated the antimicrobial efficacy of CAP towards planktonic *E*. *faecalis* on agar plates ([Fig 2](#pone.0223925.g002){ref-type="fig"}). The untreated controls (no CAP) exhibited 7.3 x 10^10^ CFU in median. CAP treatment for 1 min led to a CFU reduction of ≥ 7 log~10~ steps. Longer CAP treatment periods of 3, 5 or 10 min did further increase the killing efficacy (reductions of ≥ 8 log~10~ steps (3 or 5 min) or ≥ 9 log~10~ steps (10 min), respectively).

![Antimicrobial assay towards planktonic *E*. *faecalis* on agar plates.\
CAP was performed for different treatment periods. Surviving colonies were counted 24 h later. All results are depicted as medians, 1^st^ and 3^rd^ quartiles from six independent experiments in duplicates on a log~10~-scaled ordinate. Bars show the reductions of CFU in a log~10~ scale in comparison to untreated controls. Solid and dashed lines exhibit 3 log~10~ steps (99.9%) or 5 log~10~ steps reduction (99.999%) of CFU, respectively. (*n* = 6; untreated controls exhibited 7.3 x 10^10^ CFU in median).](pone.0223925.g002){#pone.0223925.g002}

Antimicrobial assay towards *E*. *faecalis* biofilms cultured for 24 h {#sec011}
----------------------------------------------------------------------

Secondly the antimicrobial efficacy of this new CAP device was evaluated towards *E*. *faecalis* growing as 24 h old biofilms ([Fig 3](#pone.0223925.g003){ref-type="fig"}). Untreated biofilms contained 1.9 x 10^14^ CFU in median. CAP treatment for 5 min showed a CFU-reduction by ≥ 3 log~10~ steps, while CAP treatment for 10 min resulted in a reduction by ≥ 5 log~10~ steps. Reductions for 1 and 3 min of CAP treatment were \< 3 log~10~ steps.

![Antimicrobial efficacy of CAP towards *E*. *faecalis* biofilms cultured for 24 h.\
CAP was performed for different treatment periods towards biofilms cultured for 24 h. All results are depicted as medians, 1^st^ and 3^rd^ quartiles from six independent experiments in duplicates on a log~10~-scaled ordinate. Bars show the reductions of CFU in a log~10~ scale in comparison to untreated controls. Solid and dashed lines exhibit 3 log~10~ steps (99.9%) or 5 log~10~ reduction (99.999%) of CFU, respectively. (*n* = 6; untreated controls exhibited 7.3 x 10^10^ CFU in median).](pone.0223925.g003){#pone.0223925.g003}

In addition, CHX and UVC radiation were evaluated as positive controls compared to the CAP treatment efficacy towards *E*. *faecalis* ([Fig 4](#pone.0223925.g004){ref-type="fig"}). Again, *E*. *faecalis* biofilms were cultured for 24 h. CHX 0.2% led to a CFU reduction of ≥3 log~10~ steps after 5 min while CHX 2% resulted in reduction by ≥ 9 log~10~ steps below the detection limit. A UVC radiation dose of 0.005 J/cm^2^ reduced the CFU by ≥ 5 log~10~ steps. Higher doses of 0.195 J/cm^2^ or 0.26 J/cm^2^ reduced CFU by ≥ 9 log~10~ steps below the detection limit. Overall UVC radiation as a contact-free application led to higher reduction of CFU in a dose-dependent manner compared to CAP, whereas the efficacy of CHX 0.2% treatment was similar to the CAP treatment.

![Antimicrobial efficacy of positive controls CHX and UVC radiation towards *E*. *faecalis* biofilms cultured for 24 h.\
Biofilms were incubated with CHX (0.2% or 2%) for 5 min. UVC radiation was performed applying distinct radiation doses (0.005 J/cm^2^, 0.065 J/cm^2^, 0.13 J/cm^2^ or 0.26 J/cm^2^). All results are depicted as medians, 1^st^ and 3^rd^ quartiles from six independent experiments in duplicates on a log~10~-scaled ordinate. Bars show the reductions of CFU in a log~10~ scale in comparison to untreated controls. Solid and dashed lines exhibit 3 log~10~ steps (99.9%) or 5 log~10~ reduction (99.999%) of CFU, respectively. (*n* = 6; untreated controls exhibited 7.3 x 10^10^ CFU in median).](pone.0223925.g004){#pone.0223925.g004}

Antimicrobial assay towards *E*. *faecalis* biofilms cultured for 48 h or 72 h {#sec012}
------------------------------------------------------------------------------

The previous results emphasize to investigate the antimicrobial efficacy of CAP towards biofilms cultured for longer times like 48 h or 72 h (mature biofilms). [Table 1](#pone.0223925.t001){ref-type="table"} shows the results of CAP treatment, CHX or UVC radiation towards biofilms cultured for 48 h or 72 h. The CFU of *E*. *faecalis* were reduced by ≥ 5 log~10~ steps by a CAP treatment of 10 min for both 48 h and 72 h old biofilms. CHX 2% led to CFU-reductions by ≥ 6 log~10~ steps irrespective of the culture period, while CHX 0.2% reduced the CFU by ≥4 log~10~ steps in 48 h biofilms and by ≥3 log~10~ steps in 72 h biofilms. UVC radiation led to reductions by ≥6 log~10~ steps for radiation doses of 0.065 J/cm^2^, 0.13 J/cm^2^ or 0.26 J/cm^2^.

10.1371/journal.pone.0223925.t001

###### Results from antimicrobial assay towards *E*. *faecalis* biofilms cultured for 48 h or 72 h.

![](pone.0223925.t001){#pone.0223925.t001g}

                                              Biofilm age   
  ------------------- --------------- ------- ------------- -----
  **CAP**             n/a             1 min   1.8           1.7
  n/a                 3 min           1.8     2.0           
  n/a                 5 min           2.6     2.4           
  n/a                 10 min          5.7     4.9           
  **CHX**             0.2%            5 min   4.1           3.9
  2%                  5 min           ≥ 6     ≥ 6           
  **UVC radiation**   0.065 J/cm^2^   n/a     ≥ 6           \-
  0.13 J/cm^2^        n/a             ≥ 6     \-            
  0.26 J/cm^2^        n/a             ≥ 6     \-            

n/a = not applicable

\- = not determined

This table shows the results from antimicrobial assay towards *E*. *faecalis* biofilms cultured for 48 h or 72 h. Values show log~10~ reductions

Spectroscopic measurements for release of nucleic acids upon CAP treatment {#sec013}
--------------------------------------------------------------------------

For assessing damage of cytoplasmic membranes upon CAP treatment, the release of nucleic acids from the cytoplasm was measured spectroscopically at 260 nm. Results are depicted in [Fig 5](#pone.0223925.g005){ref-type="fig"}. While the positive control showed a clear increase in median OD (0.5525) as compared to untreated controls (median OD 0.012), CAP treatment showed no increases in OD (median OD \< 0.1), irrespective whether treatment was for 5 or 10 min. These results imply that the course of inactivation does not include direct cell lysis during CAP treatment.

![Spectroscopic measurements for release of nucleic acids upon CAP treatment.\
OD medians, minima and maxima of the supernatants of untreated biofilms (UC) or biofilms treated with positive control (lysozyme treatment followed by Proteinase K digestion, (PC)) or CAP, as measured at 260 nm for release of nucleic acids. For CAP, samples were measured either 5 or 20 min after being treated with CAP for 5 or 10 min or left untreated (UC'). *n* = 6.](pone.0223925.g005){#pone.0223925.g005}

Discussion {#sec014}
==========

Cold atmospheric plasma generates a wide variety of reactive species in form of *e*.*g*. ozone, reactive oxygen species and nitrogen dioxide which are the main source for its antimicrobial efficacy \[[@pone.0223925.ref040]\]. These CAP-derived reactive species are generated by a contact-free manner and are also not highly specialized to different bacterial genera or strains. This is a major advantage in comparison to antibiotics which target only specific structures according to the so-called key-lock principle \[[@pone.0223925.ref041]\]. That is the crucial aspect in which CAP could be named superior to common antibiotics and antiseptics, which are countered by bacteria through specific mechanisms of resistance \[[@pone.0223925.ref042]\]. Up to now, the risk of bacteria developing resistance against CAP is considered minor even after multiple sublethal treatments due to the point that no specific bacterial target is in focus but rather multiple targets \[[@pone.0223925.ref014]\].

In general, two approaches are in the focus with regard to CAP. The indirect method is using an agent to submit the effective particles as it is used in plasma jets or SMD technology \[[@pone.0223925.ref043]--[@pone.0223925.ref045]\]. Such a device consists of an outer electrode and an inner electrode and the gas is pumped through and thereby ionized. This method allows a longer distance between the affected area and the CAP device \[[@pone.0223925.ref046], [@pone.0223925.ref047]\]. Such devices were already used for treating skin diseases to reduce the microbial colonization of the infected tissue. SMD technology as it is used in this study is based on the same approach as the plasma jet, but a constant flow of externally applied gas is not needed because it uses ambient air as its carrier gas. The direct method submits the effective particle directly to the surface of the treated object (*e*.*g*. patient), that means the patient operates as the counter-electrode during treatment. Limitation is the distance between operating tool and the object of treatment \[[@pone.0223925.ref048]\]. Joaquin *et al*. used an atmospheric plasma jet to effectively inactivate a biofilm produced by *Chromobacterium violaceum* \[[@pone.0223925.ref049]\]. Laroussi *et al*. reviewed an atmospheric plasma jet and distinct discharge plasma sources to inactivate different bacterial species \[[@pone.0223925.ref050]\]. Depending on the chemical composition of reactive species generated by CAP, it was demonstrated that high levels of oxygen improved the antibacterial efficacy, *e*.*g*. towards *Escherichia coli \[[@pone.0223925.ref051]\]*. Furthermore, inactivation of extracellular virulence factors by CAP is also possible. Ziuzina *et al*. showed that inactivation of different virulence factors like pyocyanin or other quorum sensing molecules in *Pseudomonas aeruginosa* was successful \[[@pone.0223925.ref052]\]. In addition, the cytotoxic effects of pyocyanin were as well effectively reduced by CAP. So far, different studies were performed with plasma devices like plasma jets and direct dielectric cold plasma devices, to affect *E*. *faecalis*, as organism of the ESKAPE pathogen group \[[@pone.0223925.ref053], [@pone.0223925.ref054]\]. Modic *et al*. showed the efficacy of CAP against biofilms formed by *Staphylococcus aureus* and *Pseudomonas aeruginosa*, which also belong to the ESKAPE pathogen group \[[@pone.0223925.ref055]\]. Moreover, other studies also demonstrated the antibacterial efficacy of cold plasmas against ESKAPE pathogens \[[@pone.0223925.ref056], [@pone.0223925.ref057]\]. Application of CAP against *E*. *faecalis* yielded promising effects, also in other environments (like in root canal treatment) when compared to photodynamic inactivation of microorganisms \[[@pone.0223925.ref058], [@pone.0223925.ref059]\]. Du *et al*. treated monospecies biofilms of *E*. *faecalis* with CAP \[[@pone.0223925.ref060]\]. They showed that the antibacterial efficacy was highest within the first 3 min and decreases after 10 and 30 min. In addition, they were able to confirm that the antibacterial efficacy of their plasma device was similar to that of 2% CHX \[[@pone.0223925.ref060]\]. Therefore, our study model is in accordance with already published papers, that *E*. *faecalis* grown as a biofilm can be successfully inactivated within a treatment period of up to 10 min. It is important to clarify that no effects on host cells and tissues occur with the use of the SMD device, since it has already been shown that CAP generated from this SMD technology exhibited no mutagenicity or toxicity against host cells and tissues *in vitro* or *ex vivo* \[[@pone.0223925.ref061], [@pone.0223925.ref062]\].

The first goal of this study was to prove that a new CAP device can kill *E*. *faecalis* seeded as planktonic cultures on agar plates. Here, a CFU-reduction of \> 7 log~10~ steps was found after 1 min of CAP treatment, while longer treatment periods showed even higher reductions of CFU. Based on these results, the next experiments were focused on biofilms formed by *E*. *faecalis*. Bacteria in biofilms are generally more tolerant against antimicrobial approaches, which poses health risks in all fields of medicine, including dentistry \[[@pone.0223925.ref009]\]. Accordingly, *E*. *faecalis* biofilms are known to be problematic to handle in the field of endodontics and have been subject to different studies in the past \[[@pone.0223925.ref024], [@pone.0223925.ref063]\]. In the present study, biofilms of *E*. *faecalis* were cultured for different periods of time to investigate potential effects of the biofilm culture period on the antimicrobial efficacy of this CAP device. In 24 h biofilms, CAP treatment showed CFU-reductions by ≥ 3 log~10~ after 5 min and ≥ 5 log~10~ after 10 min. CFU-reductions by ≥ 5 log~10~ steps could also be achieved in 48 h and 72 h old biofilms when they were subjected to CAP treatment for 10 min. Herbst *et al*. infected 50 root canals with *E*. *faecalis* and used different methods for antimicrobial treatment CFU \[[@pone.0223925.ref063]\]. The most effective methods were CHX combined with CAP followed by CHX and CAP alone. The results showed that the efficacy against *E*. *faecalis* was in the same range for CHX and CAP. Li *et al*. cultured biofilms of *E*. *faecalis* in root canals over 3 weeks and subjected them to CAP or CHX \[[@pone.0223925.ref024]\]. The results again showed similar results between CHX and CAP. After a treatment (either with CAP or CHX) for 12 min, the number of CFU was under the limit of detection. As mentioned above, the two studies by Herbst *et al*. and Li *et al*. showed that CAP was as effective as CHX for killing of *E*. *faecalis* biofilms. Here, CHX was slightly more effective irrespective of biofilm culture period. However, it must be considered that CAP works without any physical contact and may therefore be superior to CHX in terms of handling and application. In this instance, it is also noteworthy that the CAP device used in this study works with ambient air as a carrier gas in contrast to other plasma devices, which mostly use Argon or Helium as a carrier gas \[[@pone.0223925.ref062]\].

In the third part of this study, we tried to get first insights into the antimicrobial mechanism of CAP. Up to this point the mechanism of different CAP treatments were investigated for *Escherichia coli* and *Staphylococcus aureus* with different results \[[@pone.0223925.ref064]\]. Han *et al*. showed that both bacterial strains reacted in different ways to the exposition of CAP. *E*. *coli* was inactivated by cell leakage due to the damage of the lipopolysaccharides in the outer cell membrane and the thin peptidoglycan layers of the cell wall of Gram-negative bacteria. *S*. *aureus* on the other hand contains very thick peptidoglycan layers as Gram-positive bacteria compared to *E*. *coli*. Here, damage of intracellular components was observed, but the cell wall was still intact \[[@pone.0223925.ref064]\]. Therefore, we aimed to determine whether damage of cytoplasmic membranes may be the primary antimicrobial mechanism of CAP generated by SMD technology. For this purpose, release of nucleic acids upon treatment was measured spectroscopically at 260 nm \[[@pone.0223925.ref037]\]. The results showed that there was no increase in OD upon treatment with CAP, even after a duration of 5 or 20 min between CAP treatment and measurement. Therefore, the antimicrobial effects of CAP may not be due to direct damage of cytoplasmic membranes and the subsequent release of cytoplasmic constituents. That indicates that the generated reactive species may rather lead to a malfunction than to a disruption of the cell membrane by Gram-positive bacterial species. Recently, our group could demonstrate that direct damage of DNA seems not to be the primary mechanism of action of CAP due to the point that *D*. *radiodurans* could be eradicated efficiently by CAP \[[@pone.0223925.ref029]\]. *D*. *radiodurans* contains a very efficient DNA repair mechanism to survive hundreds of DNA double strand breaks by reassembling these accurately before initiation of the next cycle of cell division \[[@pone.0223925.ref065]\]. The effective inactivation of this bacterium by CAP indicates that bacterial targets other than DNA are damaged by CAP, since *D*. *radiodurans* can repair DNA damage more efficiently than *E*. *faecalis* or other bacteria \[[@pone.0223925.ref066]\]. Recently, Arjunan *et al*. summarized the current knowledge about the interactions of reactive oxygen species and reactive nitrogen species with DNA and its components generated by CAP devices, and reported that strand breaks in DNA or peroxynitrite oxidation of nucleotides take place \[[@pone.0223925.ref067]\]. Overall, we could show that this new CAP device has a pronounced antimicrobial efficacy against *E*. *faecalis* on agar plates as well as in biofilms and we could give insight into the mechanisms of action of CAP in terms of not releasing DNA and therefore not the possible problems induced by DNA damage. However, further studies on the antimicrobial mechanisms of CAP are essential for deeper understanding the effects of CAP.

Conclusions {#sec015}
===========

In this study cold atmospheric plasma was used to achieve an antibacterial reduction of \>99.9% of *Enterococcus faecalis* growing as biofilms similarly to the effect of 0.2% chlorhexidine. The superiority of CAP is the fact that it operates completely contact free. Furthermore, this study demonstrated that release of cytoplasmic components due to direct damage of the bacterial cell wall or membrane seems not to be the primary mechanism of inactivation of *E*. *faecalis* by CAP.

Supporting information {#sec016}
======================

###### Data sets necessary to replicate study findings for [Fig 2](#pone.0223925.g002){ref-type="fig"}, [Fig 3](#pone.0223925.g003){ref-type="fig"}, [Fig 4](#pone.0223925.g004){ref-type="fig"}, [Fig 5](#pone.0223925.g005){ref-type="fig"} and [Table 1](#pone.0223925.t001){ref-type="table"} are listed.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Although the idea of using cold plasmas for antimicrobial therapy is not new, the paper is dealing with an important and well investigated subject, antimicrobial effect of such plasmas against one of the ESKAPE pathogens, E.faecalis. This approach could be eficiently used for the therapy of wounds and also in dentistry.

The results are clearly presented and conclusions are supported by experimental data.

Iwould reccomend authors to expand their discussion by adding some details regarding the known effect of cold plasmas against other ESKAPE pathogens, highlighting how would this approach improve the therapy of such infections. Also discussing the antimicrobial mechanisms of cold plasmas against other microbial species, could help in revealing the primary antimicrobial mechanism against E.faecalis.

Reviewer \#2: The authors focus to demonstrate possible antimicrobial activity of CAPs on E. faecalis. The authors used CAP in both planktonic and biofilms to investigate the possible antimicrobial effects. The authors reported a decrease in CFUs after 5 and 10 minutes of CAP treatment in 24h and 72h biofilms. The authors suggest that the antimicrobial activity of CAP is not due to damage to cell membranes as they did not observe any DNA release after treatment.

My main concerns of the presented manuscript are listed below:

1\. The authors failed to explain and elaborate on the importance and possible future application of antimicrobial activity of CAP on E. faecalis. The addition of more elaborate details on the rational of choosing this bacteria to test the antimicrobial activity of CAPs would improve the quality of the introduction.

2\. Although the details of experimental plans are explained thoroughly, there are no explanation of observed results in the result section.

3\. The statistical analysis are not explained and the tests are not mentioned and the levels of significance are not reported.

4\. the details of the CAP used in this study is included in discussion and if moved to introduction, clarifies the methods and experimental plans in the study. The importance and applications suggested in the discussion can not be withdrawn from the results presented in this study are ambiguous and require further studies that shows no negative effects on host cells and tissues.

5\. Although the experiments are performed in an environment similar to human saliva, there are no explanations of the importance of use of this environment and whether other environments may impact on level of antimicrobial efficacy of CAPs.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Alina Maria Holban

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Rebuttal letter to the reviewers (a separate file was uploaded)

Review Comments to the Author

Reviewer \#1: Although the idea of using cold plasmas for antimicrobial therapy is not new, the paper is dealing with an important and well investigated subject, antimicrobial effect of such plasmas against one of the ESKAPE pathogens, E. faecalis. This approach could be efficiently used for the therapy of wounds and also in dentistry.

The results are clearly presented and conclusions are supported by experimental data.

I would recommend authors to expand their discussion by adding some details regarding the known effect of cold plasmas against other ESKAPE pathogens, highlighting how would this approach improve the therapy of such infections. Also discussing the antimicrobial mechanisms of cold plasmas against other microbial species, could help in revealing the primary antimicrobial mechanism against E.faecalis.

All changes are marked in yellow within the manuscript (file labeled as "Revised Manuscript with Track Changes").

Answer:

We thank the reviewer for the comments. We have inserted some new statements concerning efficacy of CAP against ESKAPE pathogens within the discussion section (page 17, line 365-378). Here in this study we have decided to use E. faecalis due to the fact that this pathogen is known to grew and form biofilms on both inanimate and living surfaces and therefore E. faecalis gained tolerance and susceptibility against external influences from the environment (page 19, line 426-432).

 

Reviewer \#2: The authors focus to demonstrate possible antimicrobial activity of CAPs on E. faecalis. The authors used CAP in both planktonic and biofilms to investigate the possible antimicrobial effects. The authors reported a decrease in CFUs after 5 and 10 minutes of CAP treatment in 24h and 72h biofilms. The authors suggest that the antimicrobial activity of CAP is not due to damage to cell membranes as they did not observe any DNA release after treatment.

All changes are marked in green within the manuscript. (file labeled as "Revised Manuscript with Track Changes").

My main concerns of the presented manuscript are listed below:

1\. The authors failed to explain and elaborate on the importance and possible future application of antimicrobial activity of CAP on E. faecalis. The addition of more elaborate details on the rational of choosing this bacteria to test the antimicrobial activity of CAPs would improve the quality of the introduction.

Answer:

Here in this study we used E. faecalis as one the ESKAPE pathogens which is known to be able to grew and form biofilms on both inanimate and living surfaces and therefore E. faecalis gained tolerance and susceptibility against external influences from the environment. We have added new statements on page 3, line 61-64.

2\. Although the details of experimental plans are explained thoroughly, there are no explanation of observed results in the result section.

Answer:

We have now revised the results section as recommended.

3\. The statistical analysis are not explained and the tests are not mentioned and the levels of significance are not reported.

Answer:

We thank the reviewer for the comment. Indeed, we did not explain the statistical test and did not mention the level of significance, because we did not perform classic significance analyses. However, we mentioned in the data analysis section our definition of antimicrobial efficacy and disinfection. (L230-234: This passage reads as follows: "Medians on or below these lines mean a bacterial reduction by 3 log10 (≥99.9%) or by 5 log10 (≥99.999%). According to the guideline of infection control this means a biologically relevant antimicrobial activity or a disinfectant effect, respectively \[Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol. 2002;23(12 Suppl):S3-40.\]").

From microbiological point of view concerning these definitions of the wordings "antimicrobial" and "disinfection", we used these definitions as the biological relevant tool to discriminate the data.

In addition, thoroughly reviewing our data analysis data section again, we found that the spectroscopic measurements are depicted as median min and max (see fig. 5) and not as medians, first and third quartile. We changed this part accordingly within the data analysis section.

4\. the details of the CAP used in this study is included in discussion and if moved to introduction, clarifies the methods and experimental plans in the study. The importance and applications suggested in the discussion cannot be withdrawn from the results presented in this study are ambiguous and require further studies that shows no negative effects on host cells and tissues.

Answer:

The SMD technology and the respective studies on the topic of mutagenicity against host cells and tissues are now included in the discussion section (page 18, line 389-393).

5\. Although the experiments are performed in an environment similar to human saliva, there are no explanations of the importance of use of this environment and whether other environments may impact on level of antimicrobial efficacy of CAPs.

Answer:

The human saliva was used based on the studies performed by Pratten et al. which showed that usage of saliva is requisite for growth of a robust biofilm and this method was also used in different studies before as follows:

i\) Pratten J et al.: In vitro studies of the effect of antiseptic-containing mouthwashes on the formation and viability of Streptococcus sanguis biofilms. J Appl Microbiol. 1998;84(6):1149-55;

ii\) ii) Cieplik F et al.: The impact of absorbed photons on antimicrobial photodynamic efficacy. Front Microbiol. 2015;6:706;

iii\) iii) Cieplik F et al.: Photodynamic biofilm inactivation by SAPYR\--an exclusive singlet oxygen photosensitizer. Free Radic Biol Med. 2013;65:477-87.

###### 

Submitted filename: Rebuttal letter\_\_2019.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0223925.r003

Decision Letter 1

Cartelle Gestal

Monica

Academic Editor

© 2019 Monica Cartelle Gestal

2019

Monica Cartelle Gestal

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2 Oct 2019

Antibacterial efficacy of cold atmospheric plasma against Enterococcus faecalis planktonic cultures and biofilms in vitro

PONE-D-19-18041R1

Dear Dr. Maisch,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Monica Cartelle Gestal, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear Dr. Maisch,

I am please to announce that the manuscript has been accepted in its current form.

Best regards,

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No
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Dear Dr. Maisch:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Monica Cartelle Gestal

Academic Editor

PLOS ONE
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